Compare iShares MSCI Australia ETF (EWA) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Australia ETF vs GeneDx Holdings Corp — how do they compare? iShares MSCI Australia ETF trades at $28.69, while GeneDx Holdings Corp trades at $65.64 (market cap $1.96B). The key difference: iShares MSCI Australia ETF is trading nearer its 52-week high, GeneDx Holdings Corp nearer its low. Which is the better fit depends on your goals.
| EWA | WGS | |
|---|---|---|
Sector | Broad Market / Factor | Technology |
52-Week High | $30.26 | $167.51 |
52-Week Low | $24.95 | $34.51 |
Market Cap | — | $1.96B |
Enterprise Value | — | $1.96B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWA trades at $28.66, down 0.17% on the day, with a bullish technical signal from moving averages and neutral oscillators. Key support is at $28, while resistance clusters near $29. The stock lacks disclosed financial ratios, and a dividend of $0.40 is scheduled for June 2026. Recent news highlights Australian economic factors and sector-specific developments influencing sentiment.
The outlook is mixed, with technical strength offset by limited fundamental visibility. Risks include reliance on Australian market conditions and macroeconomic headwinds. Investment appeal hinges on future financial disclosures and broader market trends.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About iShares MSCI Australia ETF
EWA tracks the MSCI Australia Index, providing broad exposure to large and mid-cap companies in the Australian equity market. It is structurally dominated by the financial and materials sectors, serving as a key instrument for investors seeking a single-country view of Australia's resource-rich and stable economy.
Read more on EWA →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
